NKP-1339: Maximum tolerated dose defined for first-in-human GRP78 targeted agent.
Dana Shelton Thompson
No relevant relationships to disclose
Glen J. Weiss
No relevant relationships to disclose
Suzanne Fields Jones
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose
Ramesh K. Ramanathan
No relevant relationships to disclose
Jeffrey R. Infante
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose
Angela Ogden
Employment or Leadership Position - Niiki Pharma, Inc.
Daniel D. Von Hoff
Research Funding - Niiki Pharma, Inc.